(R)-N-[2-(Dimethylamino)-3-pyridyl]-N"-cyano-N'-(1-phenylethyl)guanidine | 170793-38-1

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: (R)-N-[2-(Dimethylamino)-3-pyridyl]-N"-cyano-N'-(1-phenylethyl)guanidine
• 英文别名: 1-cyano-3-[2-(dimethylamino)pyridin-3-yl]-2-[(1R)-1-phenylethyl]guanidine
• CAS: 170793-38-1
• 化学式: C₁₇H₂₀N₆
• 分子量: 308.386
• InChiKey: OPPONFOLALFAJL-CYBMUJFWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  23
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  76.3
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  N'-Cyano-N-(2-dimethylamino-pyridin-3-yl)-O-phenylisourea 、 R(+)-alpha-甲基苄胺 在 N-甲基吗啉 作用下， 以 甲醇 、 乙酸乙酯 、 异丙醇 为溶剂， 生成 (R)-N-[2-(Dimethylamino)-3-pyridyl]-N"-cyano-N'-(1-phenylethyl)guanidine
  参考文献：
  名称：

  Cyanoguanidines as K-channel blockers

  摘要：

  式(I)的氰脲基化合物及其药学上可接受的酸盐，其中R.sub.1为氢或甲基；R.sub.2为C.sub.1-C.sub.6烷基，C.sub.2-C.sub.6烯基，C.sub.2-C.sub.6炔基，C.sub.3-C.sub.5环烷基，C.sub.3-C.sub.5环烯基羟甲基，甲氧基-C.sub.1-C.sub.5烷基，或R.sub.1和R.sub.2结合形成C.sub.3-C.sub.6碳环；R.sub.3和R.sub.4各自独立选择为氢，C.sub.1-C.sub.4烷基，F，Cl，Br，I或CF.sub.3；R.sub.5为氢，F或Cl；R.sub.6为氢，--NH.sub.2，--NHCH.sub.3，--NHC.sub.2 H.sub.5，--NHCH(CH.sub.3).sub.2，--N(CH.sub.3).sub.2，--N(C.sub.2 H.sub.5).sub.2，NH(CH.sub.2).sub.m，--OC.sub.1-C.sub.3烷基（其中m为2或3），--NHC(O)C.sub.1-C.sub.3烷基，Cl或Br；n为0或1。式(I)的化合物是钾通道阻滞剂，可用于治疗心血管疾病，如充血性心力衰竭和高血压，以及作为利尿剂。

  公开号：

  US05668157A1

文献信息

• CYANOGUANIDINES AS K-CHANNEL BLOCKERS
  申请人：PHARMACIA & UPJOHN COMPANY

  公开号：EP0741708A1

  公开（公告）日：1996-11-13
• US5668157A
  申请人：——

  公开号：US5668157A

  公开（公告）日：1997-09-16
• [EN] CYANOGUANIDINES AS K-CHANNEL BLOCKERS<br/>[FR] CYANOGUANIDINES UTILISEES COMME AGENTS BLOQUANTS DES CANAUX K
  申请人：PHARMACIA & UPJOHN COMPANY

  公开号：WO1995020579A1

  公开（公告）日：1995-08-03

  (EN) Cyanoguanidine compounds of Formula (I) and their pharmaceutically acceptable acid addition salts where R1 is hydrogen or methyl; R2 is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl C3-C5 cycloalkyl, C3-C5 cycloalkenyl, hydroxymethyl, methoxy C1-C5 alkyl, or R1 and R2 are combined to form a C3-C6 carboxyclic ring; R3 and R4 are each independently selected to be hydrogen, C1-C4 alkyl, F, Cl, Br, I or CF3; R5 is hydrogen, F or Cl; R6 is hydrogen, NH2, NHCH3, NHC2H5, NHCH(CH3)2, N(CH3)2, N(C2H5)2, NH(CH2)mOC1-C3 alkyl, NHC(O)C1-C3 alkyl, F, Cl, Br, C1-C3 alkyl, NH(CH2)mF, 1-imidazolyl, NHOC1-C3 alkyl, NHOH, NHSO2C1-C3 alkyl, SH, SC1-C3 alkyl, NHC(O)OC1-C3 alkyl, NHC(O)NHC1-C3 alkyl, NHSO2NHC1-C3 alkyl, NHSO2N(C1-C3 alkyl)2 or amino acid amide; R7 is C1-C7 alkyl, NH2, NHC1-C3 alkyl, N(C1-C3 alkyl)2, CF3, F, Cl, Br, I, OC1-C3 alkyl, OH, COOH, C(O)OC1-C3 alkyl, C(O)NH2, C(O)NHC1-C3 alkyl, C(O)C1-C3 alkyl, C(O)N(C1-C3 alkyl)2, SO2NH2, SO2NHC1-C3 alkyl, CN, SO2N(C1-C3 alkyl)2, NHC(O)C1-C3 alkyl, NHC(O)NHC1-C3 alkyl, NHC(O)N(C1-C3 alkyl)2, NHSO2NHC1-C3 alkyl, NHSO2N(C1-C3 alkyl)2, SH, SC1-C3 alkyl, NO2, SO2C1-C3 alkyl, NHC(O)OC1-C3 alkyl, amino acid amide or hydrogen; R8 is hydrogen, C1-C6 alkyl, NH2, NHC1-C3 alkyl, N(CH3)2, N(C2H5)2, F, Cl, Br, OC1-C3 alkyl or OH; and where m is 2 or 3 and n is 0 or 1 (except for those compounds where R8 is hydrogen and R6 is hydrogen, NH2, NHCH3, NHC2H5, NHCH(CH3)2, N(CH3)2, N(C2H5)2, NH(CH2)m-OC1-C3 alkyl, NHC(O)C1-C3 alkyl, Cl or Br). The compounds of Formula (I) are potassium channel blockers useful in the treatment of cardiovascular disorders such as congestive heart failure and hypertension and as a diuretic.(FR) L'invention se rapporte à des composés de cyanoguanidine de la formule (I) et à leurs sels d'addition acides pharmaceutiquement acceptables, formule dans laquelle R1 représente hydrogène or méthyle; R2 représente alkyle C1-C6, alcényle C2-C6, alkynyle C2-C6, cycloalkyle C3-C5, cycloalcényle C3-C5, hydroxyméthyle, méthoxy C1-C5 alkyle, ou bien R1 et R2 sont combinés pour former un cycle carbocyclique C3-C6; R3 et R4 sont chacun, indépendamment, sélectionnés parmi hydrogène, alkyle C1-C4, F, Cl, Br, I ou CF3; R5 représente hydrogène, F ou Cl; R6 représente hydrogène, NH2, NHCH3, NHC2H5, NHCH(CH3)2, N(CH3)2, N(C2H5)2, NH(CH2)mOC1-C3 alkyle, NHC(O)C1-C3 alkyle, F, Cl, Br, alkyle C1-C3 , NH(CH2)mF, 1-imidazolyle, NHOC1-C3 alkyle, NHOH, NHSO2C1-C3 alkyle, SH, SC1-C3 alkyle, NHC(O)OC1-C3 alkyle, NHC(O)NHC1-C3 alkyle, NHSO2NHC1-C3 alkyle, NHSO2N(alkyle C1-C3)2 ou un amide d'acide aminé; R7 représente alkyle C1-C7, NH2, NHC1-C3 alkyle, N(alkyle C1-C3)2, CF3, F, Cl, Br, I, OC1-C3 alkyle, OH, COOH, C(O)OC1-C3 alkyle, C(O)NH2, C(O)NHC1-C3 alkyle, C(O)C1-C3 alkyle, C(O)N(alkyle C1-C3)2, SO2NH2, SO2NHC1-C3 alkyle, CN, SO2N(alkyle C1-C3)2, NHC(O)C1-C3 alkyle, NHC(O)NHC1-C3 alkyle, NHC(O)N(alkyle C1-C3)2, NHSO2NHC1-C3 alkyle, NHSO2N(alkyle C1-C3)2, SH, SC1-C3 alkyle, NO2, SO2C1-C3 alkyle, NHC(O)OC1-C3 alkyle, un amide d'acide aminé ou hydrogène; R8 représente hydrogène, alkyle C1-C6, NH2, NHC1-C3 alkyle, N(CH3)2, N(C2H5)2, F, Cl, Br, OC1-C3 alkyle ou OH; et où m vaut 2 ou 3 et n vaut 0 ou 1 (excepté pour les composés où R8 représente hydrogène et R6 représente hydrogène, NH2, NHCH3, NHC2H5, NHCH(CH3)2, N(CH3)2, N(C2H5)2, NH(CH2)m-OC1-C3 alkyle, NHC(O)C1-C3 alkyle, Cl ou Br). Les composés de la formule (I) sont des agents bloquants des canaux de potassium utiles dans le traitement de troubles cardiovasculaires, tels que l'insuffisance cardiaque congestive et l'hypertension, et agissent également comme diurétiques.